


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Recently Viewed
PFE
Pfizer
AMST
Amesite Inc.
AFYA
Afya Limited
CYTK
Cytokinetics Incorpo
FNF
FNF Group of
Most Trending
+0.23%
-1.87%
+0.90%
+1.26%
PFE
Pfizer
$26.65
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Price Performance
$25.88 (+2.98%)
$25.72 (+3.62%)
$23.85 (+11.74%)
$26.64 (+0.04%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings decline YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
PFE Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Feb 03, 2026
Reiterate
Neutral
Goldman Sachs
Jan 16, 2026
Initiate
Neutral
UBS
Jan 12, 2026
Initiate
Neutral
UBS
Dec 30, 2025
Reiterate
Buy
Scotiabank
Dec 22, 2025
Downgrade
Hold
NVS
Novartis AG
162.67
-0.76%
NVO
Novo Nordisk A/S
47.42
-2.13%
SNY
Sanofi
46.76
-1.31%
ABBV
AbbVie
224.81
+0.21%
AZN
Astrazeneca
204.20
-1.09%
What is PFE current stock price?
What are PFE stock strengths?
What is PFE Risk Level?
What is PFE market cap and volume?
What is PFE current Stock IQ?
Should I buy PFE stock right now?
Is PFE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PFE?
What does a 'Strong Sell' rating mean for PFE?
What factors influence PFE's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
PFE
Pfizer
Current Price
$26.65
Runners Also Watch
NVS
Novartis AG
162.67
-0.76%
NVO
Novo Nordisk A/S
47.42
-2.13%
SNY
Sanofi
46.76
-1.31%
ABBV
AbbVie
224.81
+0.21%
AZN
Astrazeneca
204.20
-1.09%

PFE Price Performance
$25.88 (+2.98%)
$25.72 (+3.62%)
$23.85 (+11.74%)
$26.64 (+0.04%)
PFE Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings decline YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
PFE Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
PFE Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Latest Analysis
Is Pfizer Stock the Only Big Pharma Name Id Buy and Hold Through Any Market Crash?. Key PointsPfizer has reached a transition point following declines of some of its biggest blockbusters.
Fri Feb 20, 2026
Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial. Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17 Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer. Management noted that the combination showed significant PFS improvement and better overall [….]
Fri Feb 20, 2026
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure. PFEs oncology sales rose 8% in 2025 as Padcev Lorbrena and new launches offset Ibrance declines.
Thu Feb 19, 2026
Where is Pfizer Inc. (PFE) Headed?. Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12 Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. In another development Pfizer Inc. (NYSE:PFE) announced on February 6 that the United States Food and Drug Administration accepted and granted Priority [….]
Thu Feb 19, 2026
Top High-Yield Stocks to Double Up on Right Now. Key PointsPfizer has made the investments needed to get its drug pipeline back on track.
Thu Feb 19, 2026
Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch. Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine.
Thu Feb 19, 2026
Pfizer: Recovery Isnt Over Battered Valuation Still Discounts Its Turnaround Game.
Wed Feb 18, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.